YAP1 as a Novel Negative Biomarker of Immune Checkpoint Inhibitors for EGFR-Mutant Non-Small-Cell Lung Cancer

Figure 4

YAP1 is associated with negative tumor microenvironment in EGFR-mutant NSCLC. Spearman’s analysis showed infiltration of 22 immune cell types in NSCLC (a) and EGFR-mutant NSCLC (b) using CIBERSORT in TCGA LUAD. (c) The correlation between YAP1 expression and immune cells. (d) The mutations per coding region were evaluated in the two subtypes. (e) The tumor mutation burden (TMB) expression in the YAP1_High and YAP1_Low groups. YAP1 was negatively correlated with PD-L1 (CD274) in EGFR-mutant TCGA LUAD (f) and GSE31210 (g).

(a)

(b)

(c)

(d)

(e)

(f)

(g)